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The aim of the present work was to find out whether NPY
synthesized in human adrenal chromaffin cells controls in an
autocrine/paracrine fashion the release of catecholamines by
these cells. Accordingly, the constitutive and regulated re-
lease of both NPY and catecholamines was measured simul-
taneously in cultured human chromaffin cells. In addition, by
using both RT-PCR and a combination of specific agonists and
antagonists, we characterized the expression of NPY recep-
tors on these cells as well as their pharmacology. Our results
were as follows. 1) Human chromaffin cells constitutively se-
crete NPY. 2) Nicotine elicits a rapid increase in the release of
both catecholamines and NPY; this release of NPY is more
sustained than that of catecholamines. 3) RT-PCR shows ex-
pression of Y1, Y2, Y4, and Y5 receptor mRNA by chromaffin
cells; these receptors are functional, as various receptor spe-
cific agonists elicit an increase in intracellular calcium. 4)
Peptide YY, in contrast to NPY, is not able to stimulate the
release of catecholamines. This finding was corroborated by
the observation that no receptor-specific antagonists were
able to reduce constitutive catecholamine release, whereas an
NPY-immunoneutralizing antibody markedly attenuated the
secretion. Taken together, these data suggest that NPY orig-
inating from the adrenal medulla locally enhances the secre-
tion of catecholamines, presumably by acting via the putative
y3 receptor. (J Clin Endocrinol Metab 86: 5956–5963, 2001)
NPY is a 36-amino acid peptide present in the brain (1)and peripheral nervous system in nerve endings,
from which it is coreleased with norepinephrine (NE) during
stress (2). Several observations suggest that NPY is an im-
portant neurotransmitter involved in the central and periph-
eral control of blood pressure (3, 4). NPY stimulates at least
six types of G protein-coupled receptors, called Y1, Y2, y3,
Y4, Y5, and Y6 (5–10). Activation of the Y1 receptor by NPY
results in vasoconstriction and postsynaptic potentiation of
the catecholamine effect on blood pressure (11). NPY also
presynaptically inhibits the release of catecholamines
through the Y2 receptor (12). No functions in the cardiovas-
cular system have been associated with the Y4 and Y5 re-
ceptors. The Y6 receptor is not functional in man. The y3
receptor has not yet been cloned and is pharmacologically
characterized by its inability to be activated by peptide YY
(PYY) (13). NPY is also produced by the adrenal medulla of
various species including man (14–19) and by human pheo-
chromocytomas (20).
The reported effects of NPY on catecholamine release by
the adrenal medulla in rats (21, 22) and from bovine cells (23,
24) are conflicting depending on the experimental set-up and
the animal species. As NPY potentiates the effects of cat-
echolamines released from sympathetic nerves, we hypoth-
esized that NPY originating from the adrenal medulla might
also participate in this effect by locally regulating the secre-
tion of catecholamines by chromaffin cells. Thus, the goal of
this investigation was to examine whether in vitro NPY af-
fects the catecholamine secretory activity of isolated adrenal
chromaffin cells, and if so, which receptor(s) is responsible
for this effect.
Materials and Methods
Peptides and antagonists
NPY-(1–36), NPY-(3–36), [Leu31,Pro34]NPY, [Pro34]NPY, and PYY
were purchased from Novabiochem (Laufelfingen, Switzerland), human
pancreatic polypeptide (hPP) was obtained from Bachem (Bubendorf,
Switzerland); hNPY-(13–36), BIBP3226 (25), and BIBP3242 were gifts
from Dr. K. Hofbauer (Novartis, Basel); T4[NPY-(33–36)]4 (26) was syn-
thesized in our laboratory; the Y5 antagonist 2-[4-(2-oxo-2,3-dihydro-
benzoimidazol-1-yl)-piperidin-1-yl]-N-(9-oxo-9H-fluoren-3-yl)-acet-
amide hydrochloride was synthesized according to patent WO9835957
(27).
Adrenal glands and cell culture
The study was approved by the hospital transplantation review board
and the medical direction. Adrenal glands were obtained from kidney
transplant donors (seven women and eight men; 36  17 yr; age
range,10–62 yr). All the donors were brain-dead patients whose rela-
tives had accepted multiorgan procurement. The abdominal organs of
the donors, including the adrenal glands, were perfused in situ via aortic
cannula with University of Wisconsin solution at 4 C. The adrenals were
then procured en bloc with the kidneys and preserved in an ice bath at
4 C. Consequently, the preparation of the glands could be made im-
mediately after harvesting when surgery was performed in our own
hospital. When it was performed at a distant site this was delayed by a
maximum of 4 h. The glands were cleaned, and a cannula was inserted
into the suprarenal vein (28). The glands were then perfused with 5 ml
HBSS (136 mm NaCl, 5.4 mm KCl, 1.2 mm CaCl2, 0.44 mm KH2PO4, 0.49
mm MgCl2, 0.41 mm MgSO4, 4.2 mm NaHCO3, 0.34 mm Na2HPO4, and
Abbreviations: [Ca2]i, Intracellular free calcium concentration; EP,
epinephrine; hPP, human pancreatic polypeptide; KB, Krebs buffer; NE,
norepinephrine; PYY, peptide YY; TBST, 5 mm Tris and 0.1% Triton
X-100, pH 7.6; TH, tyrosine hydroxylase.
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5 mm d-glucose) until clear perfusate was seen dripping from the gland.
Five to 7 ml HBSS containing 0.2% collagenase, type I (Sigma, St. Louis,
MO), were then injected into the gland and shaken at 37 C for 30 min.
Thereafter, the gland was opened, and the medulla was separated from
the cortex using a scalpel by scraping off the brown interdigited islets
of chromaffin cells. The medullary tissue was chopped, collected in 10
ml 0.2% collagenase solution, and incubated for 10 min. The remaining
tissue was treated twice with 10 ml collagenase solution to fully digest
the medullary tissue. The digested tissue was further washed twice with
HBSS to remove collagenase, and cell pellets were resuspended in 15 ml
culture medium [DMEM/Ham’s F-12 (Life Technologies, Inc., Grand
Island, NY), 1:1, with 15 mm HEPES, 14 mm NaHCO3, l-glutamine (Life
Technologies, Inc.), pyridoxine (Life Technologies, Inc.), 10% inactivated
FCS (Seromed, Munich, Germany), 100 IU/ml penicillin, and 100 g/ml
streptomycin (Life Technologies, Inc.)]. Fibroblasts were removed from
the chromaffin cell preparation by plating the cells consecutively three
times for 60 min each time on different flasks, and cells were then
cultured for 2–6 d at 37 C with 5% CO2. Bovine adrenal glands were
obtained from a local slaughterhouse, and chromaffin cells were isolated
by the procedure described above.
Immunohistochemistry
Cells were cultured on glass coverslips and washed three times with
PBS, pH 7.4, before fixation with 1:1 acetone/methanol at 20 C for 15
min. Immunohistochemistry was performed as follows. After washing
twice with PBS and once with TBST (5 mm Tris and 0.1% Triton X-100
(Sigma) at pH 7.6), coverslips were incubated for 54 h at 4 C in a solution
containing antityrosine hydroxylase (anti-TH) antibody (Sigma) diluted
1:10,000, or NPY02, an anti-NPY monoclonal antibody (29), diluted
1:12,000 in TBST with 0.1% NaN3. After three washes with TBST, cells
were incubated with goat antimouse Ig (Nordic Immunological Labo-
ratories, Tilburg, The Netherlands; 1:30) and rinsed in TBST before the
addition of mouse peroxidase-antiperoxidase complex (Sternberger
Monoclonals, Inc., Baltimore, MD; 1:200) in TBST. The cells were then
washed in TBST, incubated with the peroxidase substrate/3,3-diami-
nobenzidine tetrahydrochloride solution (Polyscience, Inc., Niles, IL),
and counterstained with toluidine blue (1%). The coverslips were
destained, dehydrated in successive baths of ethanol, and mounted with
a second coverslip.
RT-PCR
Total RNA was isolated from chromaffin cells using the RNeasy kit
(QIAGEN, Chatsworth, CA). Genomic DNA was removed by digestion
with ribonuclease-free deoxyribonuclease I in the presence of RNasin
ribonuclease inhibitor. RNA was then purified by phenol/chloroform
extraction (30). cDNA was synthesized by incubating total RNA with
oligo(deoxythymidine)15 primer, RNasin, and Moloney monkey leuke-
mia virus reverse transcriptase (Promega Corp., Madison, WI) for 1 h at
37 C. PCR was performed using specific primer pairs for Y1, Y2, Y4, and
Y5 receptors and NPY (Life Technologies, Inc.). Y1 primers were: for-
ward, 5-TAT GTA GGT ATT GCT GTG ATT TG; and reverse, 5-CTG
GAA GTT TTT GTT CAG GAA; product size was 519–616 bp; annealing
temperature was 58 C (31). Y2 primers were: forward, 5-AAA TGG GTC
CTG TCC TGT GCC; and reverse, 5-TGC CTT CGC TGA TGG TAG
TGG; product size was 442 bp; annealing temperature was 66 C (32). Y4
primers were: forward, 5-CGC GTG TTT CAC AAG GGC ACC TA; and
reverse, 5-TGC CAC TTA GCC TCA GGG ACC C; product size was 376
bp; annealing temperature was 67 C (33). Y5 primers were: forward,
5-GGG TCC CCA CTT GCT TTG AGA TA; and reverse, 5-GTT CTT
TCC TTG GTA AAC AGT GAG; product size was 350 bp; annealing
temperature was 61 C (34). NPY primers were: forward, 5-TGC TAG
GTA ACA AGC GAC TG; and reverse, 5-CTG CAT GCA TTG GTA
GGA TG; product size was 386 bp; annealing temperature was 60 C (35).
Positive controls used were SK-N-MC cells for Y1 (36), LN 319 cells for
Y2 (26), human nasal mucosa for Y4 (33), and human placenta for Y5 (34)
and NPY (37). All amplifications were performed in buffer containing
1.5 mm MgCl2, 200 m dNTP (Amersham Pharmacia Biotech, Arlington
Heights, IL), 0.5 pm of each primer, and 25 U/ml hot start Taq DNA
polymerase (Perkin-Elmer Corp., Foster City, CA). Reactions were per-
formed as follows: 15 min at 95 C, 40 cycles at 95 C for 1 min, annealing
temperature for 1 min, 72 C for 1 min, and final extension at 72 C for 10
min. PCR products were analyzed by electrophoresis on a 1.5% agarose
gel containing ethidium bromide. All experiments were repeated with
chromaffin cells from three different adrenal glands.
Assay of intracellular free calcium concentration ([Ca2]i)
Chromaffin cells were cultured on glass coverslips coated with poly-
d-lysine (Sigma; 2.5 g/cm2), and [Ca2]i was determined using the
fluorescent probe fluo-3/AM (Molecular Probes, Inc., Eugene, OR) as
previously described (26). The changes in [Ca2]i were evaluated in
single cells on whole images containing 8–15 cells using the NIH image
analyzer program.
Assay of cAMP
As NPY receptors are usually coupled to Gi proteins (13), cAMP
concentrations were determined in chromaffin cells as previously de-
scribed (26). The results are expressed as femtomoles of cAMP per g
protein.
Release experiments
Perifusion. Cells were plated on glass coverslips placed in a perifusion
chamber warmed at 37 C and stabilized for 90 min at a flow rate of 0.75
ml/min with Krebs buffer (KB). Samples were then collected alternately
every 30 sec for NPY and catecholamine assays. For blockade experi-
ments, fractions were collected for catecholamine determinations every
3 min, with a flow rate of 0.35 ml/min. For catecholamine assays,
samples were acidified with 0.4 m HClO4 and quick frozen. Cat-
echolamines were extracted on alumina and determined by HPLC with
electrochemical detection (Waters Corp., Milford, MA) (28). NPY con-
centrations were measured by enzyme immunoassay (28).
Static release
Chromaffin cells were plated in 24-well plates (100,000 cells/well).
Culture medium was aspirated, and the wells were washed twice with
KB warmed to 37 C. After incubation for 10 min at 37 C with KB with
or without drugs, samples were collected and acidified with 0.4 m HClO4
and frozen. Catecholamine cell contents were extracted with KB con-
taining 0.4 m HClO4 and 10 mm EDTA. Catecholamine release was
expressed as the percentage of total intracellular content, and the effects
of the drugs in each experiment were expressed as the percent change
over the control value. Immunoneutralization of endogenous NPY has
been performed with NPYO5, a monoclonal antibody that binds to the
C-terminal part of NPY required for bioactivity at the NPY Y1 receptor
(29), and also at the Y2 and Y5 receptors (data not shown).
Statistical methods
All values are expressed as the mean sem. The data were compared
by one-way ANOVA with post-hoc analysis using unpaired t test ac-
cording to Bonferroni’s method. P  0.05 was considered significant.
Results
Human chromaffin cells in culture contain catecholamines
and NPY
Digestion of 15 glands provided 1.5–5 million chromaffin
cells/gland. Cell viability, as determined by trypan blue dye
exclusion, was generally 95%. After a few hours in culture,
chromaffin cells formed clusters of 5–20 cells, reminiscent of
the in vivo disposition of chromaffin cells in the intact adrenal
gland. Sixty percent of chromaffin cells in culture stained
positively for TH (Fig. 1A), and 30% stained positively for
NPY-like immunoreactivity (Fig. 1B). After 5 d of culture,
many cells extended neurite-like processes strongly immu-
noreactive for TH.
The catecholamine and NPY contents in chromaffin cells
were in line with the immunohistochemical observations.
Cavadas et al. • NPY and Human Adrenal Chromaffin Cells J Clin Endocrinol Metab, December 2001, 86(12):5956–5963 5957
 by on March 1, 2010 jcem.endojournals.orgDownloaded from 
Intracellular contents were 314  128 fmol NPY/105 cells
(mean  sd of six different cell cultures), 166  148 pmol
NE/105 cells (mean  sd; n  13; range  5–87) and 251 
65 pmol epinephrine (EP)/105 cells (mean  sd; n  13;
range, 7–137). The ratio of NE and EP in each culture was
relatively constant (38  6% for NE and 62  6% for EP).
Dissection of adrenal gland followed by plating and 4 d of
cell culture did not change the proportion of NE relative to
EP in chromaffin cells. On a molar basis, cells contain 1250-
fold more catecholamines than NPY.
Differential response of catecholamine and NPY release
to nicotine
In perifused chromaffin cells, catecholamines and NPY
were constitutively released (Fig. 2A). NE, EP, and NPY were
secreted at rates of 0.022  0.002%, 0.018  0.008%, and
0.04  0.01% of intracellular content/0.5 min, respectively.
Nicotine (100 m) infusion for 10 min increased the release
of both NPY and catecholamines by about 7- and 4-fold,
respectively (Fig. 2, B and C). The pattern of secretion was
divided into two phases; a few seconds after exposure to
nicotine, NE, EP, and NPY secretion was enhanced, with a
peak at 2 min. However, NE and EP secretion returned to
baseline within 5 min, whereas 25 min after removal of nic-
otine, the NPY secretion rate was still increased (Fig. 2A).
Human chromaffin cells express NPY and NPY receptors
Next, we investigated which NPY receptor subtypes were
expressed by chromaffin cells in culture. We analyzed RNA
isolated from cells obtained from three different subjects for
the presence of NPY, Y1, Y2, Y4, and Y5 mRNAs by RT-PCR.
We detected mRNA for NPY and Y1, Y2, Y4, and Y5 receptors
in all samples (Fig. 3).
Signal transduction induced by NPY receptors
We then examined the functional pharmacology of NPY
receptors expressed on individual human chromaffin cells by
measuring [Ca2]i increases evoked by NPY. NPY induced
a rapid increase in [Ca2]i, followed by a relatively long-
lasting decrease, possibly due to calcium entry (Fig. 4A). The
basal [Ca2]i level was 158 12 nm (n 312). NPY (100 nm)
caused an increase in [Ca2]i by 245  65 nm (Table 1). NPY
stimulated 21% of the cells at 10 nm and 31% at 100 nm. PYY,
[Leu31,Pro34]NPY a Y1/Y5 agonist, and NPY13–36 or
TASPV, selective Y2 agonists (38), increased [Ca2]i in chro-
maffin cells, all at 100 nm (Table 1). In contrast, hPP (100 nm;
Y4 agonist) weakly increased cytosolic calcium release. These
data are in agreement with RT-PCR experiments indicating
that Y1/Y5, Y2, and Y4 receptors are expressed on chromaf-
fin cells.
We investigated the effect of NPY on the response to
agents that stimulate adenylate cyclase. NPY inhibited for-
skolin-stimulated cAMP accumulation in two cultures ob-
tained from two different glands (Fig. 4B), with maximal
inhibition (42%) at 5 nm NPY. These results suggest func-
tional coupling of NPY receptors and adenylate cyclase ac-
tivity in chromaffin cells.
NPY stimulates catecholamine secretion
To evaluate the effect of NPY on catecholamine secretion,
we incubated chromaffin cells for 10 min with 1–100 nm NPY,
and observed a 30–60% increase in catecholamine release
over the control value (Fig. 5).
NPY analogs, but not PYY, evoke catecholamine release
To characterize the receptor(s) involved in catecholamine
release, different NPY selective agonists were studied in
FIG. 1. Staining of human chromaffin cells with antibodies against
TH (A) and NPY (B).
FIG. 2. Constitutive and regulated release of NPY, NE, and EP from
human chromaffin cells. The cells were plated onto two glass cover-
slips and introduced in a perifusion chamber. Every 30 sec, perifusion
samples were collected alternatively for NPY and catecholamine as-
says. A, Release of NPY(F), NE (), and EP (E) is expressed as a
percentage of the intracellular content. The amounts of NPY (B), NE
(; C), and EP (f; C) released per min (constitutive release) or with
nicotine (100M; regulated release) are indicated. One representative
experiment of three is shown.
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static release experiments. hPP (Y4 agonist), NPY-(13–36) (Y2
agonist), and NPY-(3–36) (Y2/Y5 agonist) evoked catechol-
amine secretion at 100 nm. Surprisingly, exposure to 100 nm
[Leu31,Pro34]NPY, [Pro34]NPY (Y1/Y5 agonists), or PYY did
not elevate catecholamine release (Fig. 5).
The rank order of potency of NPY and analogs in terms of
stimulation of catecholamine secretion was: NPYNPY-(13–
36), NPY-(3–36), PP34ProNPY  [Leu31,Pro34]NPY 
PYY, which is most consistent with the involvement of a
receptor of the putative y3 receptor subtype (36, 39–41).
NPY has a tonic role on catecholamine release by
chromaffin cells
We then studied the effects of different NPY receptor an-
tagonists to assess the involvement of endogenous NPY on
catecholamine secretion by chromaffin cells. Cells were pre-
incubated with 1 m BIBP 3226 (Y1 antagonist) or its inactive
isomer BIBP 3242 (25), T4 [NPY-(33–36)]4 (Y2 antagonist)
(26), or 100 nm of a Y5 antagonist (27). None of these sig-
nificantly altered the constitutive release of catecholamines
in either static or perifusion systems (Fig. 6A). These results
are consistent with our previous postulate that a y3 receptor
may be responsible for catecholamine release. To determine
whether NPY stimulates catecholamine secretion through a
non-Y1, -Y2, and -Y5 receptor via an autocrine/paracrine
loop, we used an anti-NPY monoclonal antibody, NPY05, for
immunoneutralization experiments. NPY05 caused signifi-
cant reductions of the basal release of NE and EP by 35% and
28%, respectively (Fig. 6, B and C). The reduction of cate-
cholamine secretion induced by NPY05 was progressive and
lasted even after removing the antibody from the perifusion
medium (Fig. 6B); NPY05 did not affect all stimuli to cate-
cholamine secretion, as KCl depolarization still evoked large
releases of NE and EP. To rule out the possibility of a non-
specific effect of NPYO5, we used an unrelated IgG, directed
against the C-flanking peptide of NPY (CPON01), as a neg-
ative control (42) at the same concentration as NPYO5.
CPON01 was devoid of any effect on catecholamine secretion
(Fig. 6A).
Discussion
The present data demonstrate that human adrenal chro-
maffin cells constitutively secrete catecholamines and NPY,
and that NPY stimulates the release of catecholamines. The
data obtained with various selective agonists and antagonists
FIG. 3. Expression of NPY Y1, Y2, Y4, and Y5 receptors. NPY re-
ceptor and NPY mRNAs were detected in primary cultured human
adrenal chromaffin cells and control tissues. These data are repre-
sentative of three or four different cell preparations obtained from
different donors. cDNAs synthesized from total RNA of human tissues
were used as templates for PCR reactions using specific primers. Lane
1, Negative PCR control (no template); lane 2, positive control; lane
3, RNA of chromaffin cells without reverse transcriptase; lane 4, RNA
of chromaffin cells with reverse transcriptase.
FIG. 4. Signal transduction pathways activated by NPY receptors on
human chromaffin cells. A, NPY increased [Ca2]i release from hu-
man chromaffin cells. NPY caused a transient free calcium rise that
reached a peak in 10 sec and returned to basal levels within 50 sec.
This trace is representative of 20 different recordings. B, NPY inhib-
ited forskolin-stimulated cAMP accumulation in chromaffin cells.
Cells (100000/well) were incubated with 10 M papaverine, 1 M
forskolin, and different concentrations of NPY, and cAMP was mea-
sured. Data are the mean of two separate experiments performed in
triplicate.
TABLE 1. Effect of NPY and analogs on [Ca2]i of chromaffin
cells
n
[Ca2]i (nM) in
the total cell
population
[Ca2]i (nM)
in responding
cells
% of
responding
cells
Basal 358 158  12 0 0
NPY (100 nM) 154 183  29 245  65 31
NPY (10 nM) 34 202  38 188  79 21
PYY (100 nM) 33 188  34 214  86 27
[Leu31,Pro34]NPY
(100 nM)
39 238  47 191  86 15
NPY(13–36) (100
nM)
44 150  24 183  88 14
PP (100 nM) 68 160  39 17  6 9
TASP-V (100 nM) 37 284  103 226  155 40
Data were obtained from five different glands. n, The total number
of cells undergoing individual calcium measurement. Responding
cells represent the proportion of cells that increase their free cytosolic
calcium by at least 2 SD over the mean of basal fluctuation of [Ca2]i
(10 nM). Data are expressed as the mean  SEM increase in [Ca2]i in
responding cells.
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suggest that NPY elicits catecholamine release by stimulating
the putative y3 receptor, in that NPY05, an anti-NPY mono-
clonal antibody used to neutralize endogenous peptide re-
leased from cells, but not Y1, Y2, or Y5 antagonists, reduced
the constitutive release of catecholamines from chromaffin cells.
These data taken together suggest that NPY released from chro-
maffin cells may act in an autocrine/paracrine manner to mod-
ulate catecholamine secretion from chromaffin cells.
FIG. 5. Effects of exogenous NPY and analogs (at 100 nM) on NE () and EP (f) release from chromaffin cells. Cells were incubated for 10 min
at 37 C in KB (basal) or in the presence of different NPY analogs, and catecholamines were measured by HPLC. Data are expressed as the percent
increase in release compared with basal (mean  SEM of experiments with one to eight different adrenal glands performed in triplicate). *, P 
0.05 compared with basal (by unpaired t test according to Bonferroni’s method).
FIG. 6. Endogenous NPY is involved in tonic catecholamine release from chromaffin cells. A, Effects of different NPY antagonists on basal
release of NE () and EP (f) by chromaffin cells. Cells were preincubated for 30 min with 1 M Y1 and Y2 antagonists, 100 nM Y5 antagonist,
and 6 g/ml NPY05 or CPON01 antibodies, and release of NE and EP was measured for 10 min. Data are expressed as the percent change
in catecholamine release compared with basal release (mean  SEM of experiments with three to eight different adrenal glands performed in
triplicate). *, P 0.05 compared with basal (by unpaired t test according to Bonferroni’s method). B, Immunoneutralization of endogenous NPY
by NPY05 decreases the catecholamine secretion rate. Cells were perifused with KB, and fractions were collected every 3 min for catecholamine
assay. The antibody NPYO5 (6 g/ml) was added at fraction 5 (15 min), and 56 mM KCl was added at fraction 25 (75 min). Release of NE ()
and EP (F) is expressed as a percentage of the intracellular content. C, Amounts of NE () and EP (f) released per min. The area under the
curve (AUC) of catecholamine release from cells was divided by the duration of perifusion (60 min) with KB (basal) or NPYO5 (6 g/ml). The
mean  SEM of perifusion performed using three different adrenal glands are shown. *, P  0.05 compared with basal (by t test).
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We first established our primary cell culture of adrenal
chromaffin cells and demonstrated that the ratio of NE to EP
found in our cell culture was constant over the time of cell
culture and similar to that we found in the intact adrenal
gland. However, this ratio (62%) is relatively high compared
with that previously reported in the intact human adrenal
gland, where NE was found to be only 10% of total cat-
echolamines (43). A possible explanation is that the adrenals
used in our studies were preserved in an organ conservation
solution, whereas in previous studies chromaffin cell ho-
mogenates were prepared from adrenal medulla dissected
from patients at autopsy, with no indication of the time lag
between death and tissue preparation (43).
We then found that NPY induced the secretion of cat-
echolamines by human chromaffin cells. The present data
contrast with other studies showing a weak inhibitory effect
of NPY on NE and EP release from bovine chromaffin cells
evoked by a cholinergic agonist (23). Conflicting results,
however, have also been seen in perfused bovine adrenal
glands, where NPY was shown to stimulate the secretion of
catecholamines in the presence of cholinergic agents (24). We
performed similar studies to ensure that our experimental
system was not responsible for this discrepancy and found
that NPY inhibits the cholinergic-induced secretion of cat-
echolamines from bovine chromaffin cells by 20% (data not
shown).
The effect of NPY in the adrenal medulla of other species
is not clearly established; for instance, although NPY evokes
the release of catecholamines from intact rat adrenal capsular
tissue (21), it has also been reported that NPY immunoneu-
tralization enhances the nicotine-mediated release of cat-
echolamines from cultured rat adrenal chromaffin cells (22).
It therefore, appears that the effect of NPY on the adrenal
medulla depends on the experimental conditions used and
the animal species studied.
RT-PCR experiments on mRNA extracted from cultured
chromaffin cells indicated that NPY, Y1, Y2, Y4, and Y5
receptors are expressed. However, these data must be inter-
preted cautiously. Although differential plating allows pref-
erential selection of chromaffin cells over fibroblasts, we
cannot exclude the possibility that some cortical cells may
contaminate our preparations. Therefore, the crucial step in
determining the NPY receptor involved in catecholamine
secretion was to use selective NPY agonists in the functional
tests of catecholamine secretion. The rank order of potency
of NPY and analogs in terms of stimulation of catecholamine
secretion was: NPY (Y1/Y2/y3/Y4/Y5)NPY-(13–36) (Y2),
NPY-(3–36) (Y2/Y5), PP (Y4)[Leu31,Pro34]NPY 
[Pro34]NPY (Y1/Y4/Y5) PYY (Y1/Y2/Y4/Y5), suggesting
the involvement of the y3 receptor subtype (36, 39–41). A
common feature of y3 receptors is their inability to be acti-
vated by PYY. However, our data contrast with those re-
ported with bovine chromaffin cells suggesting the involve-
ment of y3 and Y1 receptors in catecholamine secretion (23,
24, 36, 39).
Relatively few tissues that express y3 receptors have been
identified: bovine adrenal chromaffin cells (23, 36, 39), rat
superior cervical ganglia sympathetic neurons (44), rat nu-
cleus tractus solitarii (45), rat cardiac ventricular membranes
(46), rat distal colon (41), and PC12 cells differentiated with
nerve growth factor (47). Also, the potency of NPY analogs
on y3 receptors depends on the species and tissues studied;
for instance, [Pro34]NPY is effective in bovine chromaffin
cells and rat nucleus tractus solitarius, but not in human
chromaffin cells; NPY-(13–36) is effective in human and bo-
vine chromaffin cells, but not in PC-12 cells or rat nucleus
tractus solitarius; [Leu31,Pro34]NPY can stimulate the y3 re-
ceptor of PC-12 cells and rat distal colon, but not human
chromaffin cells (23, 26, 40, 41, 47). Therefore, Y1, Y2, Y4, and
Y5 receptors, despite their presence on chromaffin cells, do
not appear to be implicated in NPY-evoked catecholamine
release from human chromaffin cells.
The fact that NPY stimulates catecholamine release from
human chromaffin cells raises the question of whether en-
dogenous NPY plays a tonic role in catecholamine secretion.
To address this question, we used Y1, Y2, and Y5 receptor
antagonists and established that these compounds had no
effect on basal catecholamine release. In the absence of spe-
cific y3 antagonists, we neutralized endogenous NPY with
NPYO5, an anti-NPY monoclonal antibody that significantly
reduced the basal release of catecholamines (29), thus sug-
gesting that endogenous NPY modulates catecholamine se-
cretion in chromaffin cells. Unfortunately, the absence of y3
antagonists precludes clinical experiments to assess this
mechanism in humans.
With regard to cell signaling, NPY significantly decreased
forskolin-stimulated cAMP accumulation, in contrast with
reports on bovine chromaffin cells that NPY had no effect on
adenylate cyclase activity (36). An intriguing question re-
mains concerning the effect of NPY agonists on calcium
mobilization. In our studies, PYY, [Leu31,Pro34]NPY, and
[Pro34]NPY increased [Ca2]i, presumably via Y1, Y2, Y4, or
Y5 receptors. As the major signal for catecholamine exocy-
tosis in chromaffin cells is an increase in [Ca2]i, via calcium
entry rather than mobilization of intracellular Ca2 stores,
we suggest that the y3 receptor is probably the only receptor
to be efficiently coupled to the calcium increase-exocytosis
mechanism via the influx of Ca2 (48).
The finding that nicotine, during the first phase of stim-
ulation, evokes a simultaneous release of NPY, EP, and NE
from chromaffin cells might reflect a common storage of NPY
within NE and/or EP granules. Consequently, our data do
not support two conflicting immunohistochemical reports
that NPY is selectively colocalized with EP (46) or NE (49).
We postulate that during the initial phase of release, NPY acts
on NPY y3 receptors to amplify catecholamine release. More-
over, although NPY and catecholamines might in some in-
stances be located in common vesicles, the prolonged secre-
tion of NPY (even beyond the end of nicotine infusion) favors
a distinct pool of vesicles containing mainly NPY available
for exocytosis during the phase when catecholamine secre-
tion returned to constitutive levels.
At the periphery, NPY is colocalized with NE and released
from sympathetic nerve terminals upon sympathetic stim-
ulation (2–4). NPY potentiates the vasoconstrictor effect of
NE in rats (11) as well as humans (50) through the Y1 re-
ceptor. In addition to the sympathetic nervous system, we
previously found that the rat adrenal was a significant source
of NPY, as circulating NPY levels in rats are 35% lower in the
absence of adrenal medulla (51), but similar data in man are
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lacking. Therefore, NPY released from the adrenal medulla
may contribute to the increase in blood pressure observed
during sympathoadrenal stimulation; this is probably the
case for the cold water test, as NPY Y1 antagonist adminis-
tration attenuates the elevation in blood pressure seen during
this test in rats (52). Therefore, we postulate a dual role of
NPY as a neurotransmitter (originating from the nerve end-
ings) and a hormone (deriving from the adrenal).
In conclusion, the present study suggests a new role for
NPY as a local hormone that modulates catecholamine ac-
tions during stress, and it is postulated that this function is
mediated via the y3 receptor in man. Consequently, better
understanding of the y3 receptor might allow the develop-
ment of specific receptor antagonists that could be useful for
treating hyperadrenergic states as well as patients with pheo-
chromocytoma and increased secretion of NPY associated
with hypertensive crises.
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